TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17050753

Group type: EXPERIMENTAL
Intervention: Telephone Support Group (TSG)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 97
Study: 12790207

Group type: EXPERIMENTAL
Intervention: Alfentanil at target concentrations of 150, 225, and 300 ng mL(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol added to alfentanil infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alfentanil target concentration cA0 = 1240 (51) ng mL(‐1) and propofol concentration cP0 = 5.21 (0.36) microg mL(‐1)
Number of subjects: 20
Study: 10335220

Group type: EXPERIMENTAL
Intervention: Social intervention through management modification (goal setting and role modeling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Architectural modification (physical intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control unit with no planned change
Number of subjects: 0
Study: 8953336

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion in Group 1
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion in Group 2
Number of subjects: 2

Group type: COMPARATOR
Intervention: Active warm-down (AWD)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (PLA) in Group 1
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (PLA) in Group 2
Number of subjects: 2
Study: 1773095

Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (5 mg) at bedtime (2200 hr) for 3 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (7 mg at 2100 hr)
Number of subjects: 5
Study: 7046937

Group type: EXPERIMENTAL
Intervention: Propranolol-hydrochlorothiazide combination (n = 47)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Propranolol alone (n = 51)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone (n = 52)
Number of subjects: 158
Study: 31879028

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1201

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1201
Study: 29450523

Group type: EXPERIMENTAL
Intervention: PERC group (n=962)
Number of subjects: 1916

Group type: COMPARATOR
Intervention: Control group (n=954)
Number of subjects: 1916
Study: 26763913

Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy within the first five days after intubation
Number of subjects: 380

Group type: COMPARATOR
Intervention: Ongoing orotracheal intubation with consecutive weaning and extubation, and if failed, percutaneous tracheostomy from day 10 after intubation
Number of subjects: 380
Study: 24948511

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg once daily, orally)
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Glimepiride (1-4 mg once daily, orally)
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1549
Study: 22406192

Group type: EXPERIMENTAL
Intervention: Smoke Free and Living It© behavioral intervention
Number of subjects: 255
Study: 20104069

Group type: EXPERIMENTAL
Intervention: Citalopram (20‐40 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18050186

Group type: EXPERIMENTAL
Intervention: Submaximal oxygen uptake (VO(2submax))
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Peak VO(2) (VO(2peak))
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Anaerobic power using modified Wingate tests (W(ant))
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Childhood Health Assessment Questionnaire (C-HAQ)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Revised Activity Scale for Kids (ASK)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Habitual Activity Estimation Scale (HAES) total activity score
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Habitual Activity Estimation Scale (HAES) very active hours
Number of subjects: 74
Study: 16259546

Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Venlafaxine XR (75-225 mg/day)
Number of subjects: 163
Study: 12107316

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated stainless-steel Schanz pins
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard titanium Schanz pins
Number of subjects: 46
Study: 9668744

Group type: EXPERIMENTAL
Intervention: Volunteer peer counseling program
Number of subjects: 143
Study: 8035044

Group type: EXPERIMENTAL
Intervention: Transient bacteremia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sustained bacteremia
Number of subjects: 60
Study: 3055720

Group type: EXPERIMENTAL
Intervention: 2 x 1 g carnitine orally for one week and 1 x 1 g carnitine for the following 7 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 15
Study: 29754664

Group type: EXPERIMENTAL
Intervention: In-hospital CV prevention consult (PC; group B)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PC plus behavioral intervention program (group C)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (UC; group A)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PC groups (B and C combined)
Number of subjects: 400
Study: 27760869

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care plus education
Number of subjects: 70
Study: 24717908

Group type: EXPERIMENTAL
Intervention: Low-dose remifentanil (0.1 μg/kg/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (0.25 μg/kg/min)
Number of subjects: 14
Study: 22824930

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg for the first 3 days followed by 5 mg/day, reduced to 2.5 mg/day on the first postoperative day)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 445
Study: 20422360

Group type: EXPERIMENTAL
Intervention: Rexflavone (Sophorae fructus extract)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19127085

Group type: EXPERIMENTAL
Intervention: Pharmacological prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis
Number of subjects: 0
Study: 16398838

Group type: EXPERIMENTAL
Intervention: Goat milk infant formula (GMF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cow milk infant formula (CMF)
Number of subjects: 72
Study: 16327967

Group type: EXPERIMENTAL
Intervention: Daily visit from a communicator/facilitator
Number of subjects: 83

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 83
Study: 11590503

Group type: EXPERIMENTAL
Intervention: Treatment combinations of registered antiretroviral drugs (specific regimens not detailed)
Number of subjects: 0
Study: 9262295

Group type: EXPERIMENTAL
Intervention: Slow controlled-rate freezing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rapid cooling
Number of subjects: 0
Study: 8098293

Group type: EXPERIMENTAL
Intervention: Nutritional factors and relative rest in the left lateral position
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard antenatal control
Number of subjects: 74
Study: 3303899

Group type: EXPERIMENTAL
Intervention: Bush potato (Ipomoea costata)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Potato (Solanum tuberosum)
Number of subjects: 2
Study: 2789483

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram/kg prior to induction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms/kg prior to induction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol alone (Control Group C)
Number of subjects: 60
Study: 31858212

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum HEAL9
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei 8700:2
Number of subjects: 44

Group type: COMPARATOR
Intervention: Probi Defendum®
Number of subjects: 44
Study: 30930034

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training in a game‐like format
Number of subjects: 150

Group type: COMPARATOR
Intervention: Active control (computer games)
Number of subjects: 150
Study: 29269937

Group type: EXPERIMENTAL
Intervention: Purified rice endosperm protein (REP) supplementation (5 g/day for 4 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25693609

Group type: EXPERIMENTAL
Intervention: Revexepride 0.1 mg three times daily
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Revexepride 0.5 mg three times daily
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Revexepride 2.0 mg three times daily
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 23300275

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20938767

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day) for up to 24 months
Number of subjects: 758
Study: 19245380

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 41
Study: 17124641

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 15695501

Group type: COMPARATOR
Intervention: Bolus 5-FU/LV (5-FU 425 mg/m2 i.v. and LV 20 mg/m2 i.v. bolus days 1-5 every 28 days for 6 months)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: PVI 5-FU (300 mg/m2/day for 12 weeks)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Bolus 5-FU/LV
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: PVI 5-FU
Number of subjects: 801
Study: 11933922

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 9337378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Bupropion 100 mg
Number of subjects: 615
Study: 7892806

Group type: EXPERIMENTAL
Intervention: Rogerian‐based peer facilitation skills training
Number of subjects: 104

Group type: COMPARATOR
Intervention: Untrained college students taking a course in behavioral psychology
Number of subjects: 104
Study: 2853055

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICI 118551 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg + ICI 118551 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg + ICI 118551 25 mg
Number of subjects: 0
Study: 29294116

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 500

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 500
Study: 28604144

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 131
Study: 25760887

Group type: EXPERIMENTAL
Intervention: High-intensity LED light (3200 mW/cm(2)) cured for 6 seconds
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard-intensity LED light (1200 mW/cm(2)) cured for 20 seconds
Number of subjects: 34
Study: 23709132

Group type: EXPERIMENTAL
Intervention: Using a picture book during blood withdrawal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No local anaesthesia with picture book
Number of subjects: 120

Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 120
Study: 21052022

Group type: EXPERIMENTAL
Intervention: β-blocker or diuretic monotherapy
Number of subjects: 5152

Group type: EXPERIMENTAL
Intervention: β-blocker and/or diuretic treatment
Number of subjects: 5152

Group type: COMPARATOR
Intervention: diltiazem treatment
Number of subjects: 5152
Study: 18569138

Group type: COMPARATOR
Intervention: Zolpidem 10 mg nightly for 14 nights (Control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Symptom-oriented hypnotherapy, twice-a-week 1.5-hour sessions for 2 weeks (Intervention group)
Number of subjects: 32
Study: 17135629

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Lifestyle modification program
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234
Study: 14575233

Group type: EXPERIMENTAL
Intervention: Combination of ofloxacin and tinidazole
Number of subjects: 60
Study: 11128874

Group type: EXPERIMENTAL
Intervention: Runners training in urban areas (n=69)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Runners training in rural areas (n=21)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nonrunners (n=30)
Number of subjects: 120
Study: 8806332

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) with adjunctive antithrombotic therapy (hirudin or heparin)
Number of subjects: 0
Study: 2005228

Group type: EXPERIMENTAL
Intervention: 0.2% triclosan mouthwash
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1% sodium lauryl sulphate (SLS) mouthwash
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 16

Group type: COMPARATOR
Intervention: saline control rinse
Number of subjects: 16
Study: 6824189

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental 400 tablets with 400 mg active ingredient)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31075225

Group type: EXPERIMENTAL
Intervention: Simulation-based education (computer-based e-learning tool with clinical scenarios)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Simulation-based education
Number of subjects: 247

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 247
Study: 29724511

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 0

Group type: COMPARATOR
Intervention: MenC-CRM197
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACWY-TT (booster dose)
Number of subjects: 0
Study: 27266861

Group type: EXPERIMENTAL
Intervention: Alert in primary care electronic medical records (EMRs) for 1 year
Number of subjects: 41442

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41442
Study: 24732752

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no fluvastatin)
Number of subjects: 116
Study: 22802220

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (8‐ to 12‐week treadmill exercise program, target lactate 2.0±0.5 mmol/L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 50
Study: 20447012

Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 45
Study: 17903340

Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (38 % fat, 22 % MUFA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: SFA-rich diet (38 % fat, 20 % SFA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Carbohydrate-rich diet (30 % fat, 55 % carbohydrate)
Number of subjects: 59
Study: 16552651

Group type: EXPERIMENTAL
Intervention: Bupivacaine (n: 17)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ropivacaine (n: 18)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (n: 20)
Number of subjects: 55
Study: 11792602

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Normal diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 53

Group type: COMPARATOR
Intervention: Insulin tolerance test
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Food intake (protein and fat)
Number of subjects: 53
Study: 10430379

Group type: EXPERIMENTAL
Intervention: High dose octreotide (0.5 microg/kg/hr by continued i.v. infusion)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High dose octreotide
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 7582405

Group type: EXPERIMENTAL
Intervention: Modified Robert Jones Bandage (MRJB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Elastic Support Bandage (ESB)
Number of subjects: 40
Study: 2190515

Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisone, 60 mg/d for 7 days, followed by a progressive tapering over 14 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 37
Study: 365800

Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) 30 microgram
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) 40 microgram
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) 20 microgram
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) 10 microgram
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31987512

Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention (including sit-stand workstations, group sessions, activity/sitting trackers)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 244
Study: 31230397

Group type: COMPARATOR
Intervention: H2 RAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined H2 RAs and PPIs
Number of subjects: 0
Study: 29110647

Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once-weekly
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 26283094

Group type: EXPERIMENTAL
Intervention: I Move (self-determination theory and motivational interviewing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active Plus (traditional health behavior theories)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 23331534

Group type: EXPERIMENTAL
Intervention: PĒCO2 at hypoventilation (43 mmHg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PĒCO2 at normoventilation (33 mmHg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PĒCO2 at hyperventilation (23 mmHg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PĒCO2 at apnea
Number of subjects: 23
Study: 20505438

Group type: COMPARATOR
Intervention: Bapineuzumab 0.5 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bapineuzumab 1.5 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bapineuzumab 5.0 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (all doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18389741

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted right hemicolectomy (LRH)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Open right hemicolectomy (ORH)
Number of subjects: 66
Study: 17062427

Group type: EXPERIMENTAL
Intervention: Direct trainer‐trainee interaction
Number of subjects: 83

Group type: COMPARATOR
Intervention: Self‐paced computer‐assisted training
Number of subjects: 83

Group type: COMPARATOR
Intervention: On‐line training with real‐time audio‐visual interaction
Number of subjects: 83
Study: 14552502

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical data
Number of subjects: 0
Study: 11832135

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin 1 microg x kg(‐1) x min(‐1) perioperatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no nitroglycerin)
Number of subjects: 40
Study: 1635566

Group type: EXPERIMENTAL
Intervention: Dacarbazine plus tamoxifen
Number of subjects: 117

Group type: COMPARATOR
Intervention: Dacarbazine alone
Number of subjects: 117
Study: 6733563

Group type: EXPERIMENTAL
Intervention: Intravenous misonidazole with 10 fractions of 400 rad each
Number of subjects: 38

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 38
Study: 31387061

Group type: EXPERIMENTAL
Intervention: High Power Poses (HPP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low Power Poses (LPP)
Number of subjects: 56
Study: 29605036

Group type: EXPERIMENTAL
Intervention: Ketamine PCA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydromorphone PCA
Number of subjects: 20
Study: 26691888

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg thrice-daily for 6 months
Number of subjects: 39
Study: 24508083

Group type: EXPERIMENTAL
Intervention: Cold-water cooling of tonsillar fossa and pharyngeal mucosa with 4 °C saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: No cooling (Control)
Number of subjects: 40
Study: 22909799

Group type: EXPERIMENTAL
Intervention: Hand-video-assisted thoracoscopy surgery (HVATS) esophagectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PET/CT scan
Number of subjects: 80
Study: 20444503

Group type: EXPERIMENTAL
Intervention: Combined treatment (pharmacological + psychoeducational and cognitive-behavioral therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard pharmacological treatment
Number of subjects: 40
Study: 17903569

Group type: EXPERIMENTAL
Intervention: Hypopharyngeal packing
Number of subjects: 144
Study: 15625142

Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl/estradiol plus 3 mg drospirenone (group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl/estradiol plus 75 microg gestodene (group B)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy controls (group C)
Number of subjects: 71
Study: 12413987

Group type: EXPERIMENTAL
Intervention: OGTT with IV injection of naloxone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: HRT (estro‐progestin combined therapy)
Number of subjects: 21

Group type: COMPARATOR
Intervention: OGTT (saline study)
Number of subjects: 21
Study: 10207542

Group type: EXPERIMENTAL
Intervention: HIV-1 p24 antibody
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: HIV-1 p24 antibody < 5 RTU
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: HIV-1 RNA
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: CD4 cell percentage
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: ICD p24 antigen
Number of subjects: 218